Get the Stockscreener App
74.05
0.36%
-0.27
After Hours:
74.05
Spyre Therapeutics Inc stock is traded at $74.05, with a volume of 574.91K.
It is down -0.36% in the last 24 hours and up +1.44% over the past month.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$74.32
Open:
$75.34
24h Volume:
574.91K
Relative Volume:
0.53
Market Cap:
$6.43B
Revenue:
$688.00K
Net Income/Loss:
$-168.74M
P/E Ratio:
-31.41
EPS:
-2.3577
Net Cash Flow:
$-185.87M
1W Performance:
-1.16%
1M Performance:
+1.44%
6M Performance:
+205.23%
1Y Performance:
+391.37%
1-Day Range:
$73.11
$75.63
1-Week Range:
$64.67
$75.65
52-Week Range:
$13.93
$78.80
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
74.05 | 6.45B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-26-25 | Initiated | Deutsche Bank | Buy |
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
SYRE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SYRE Technical Analysis | Trend, Signals & Chart Patterns | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
Spyre Therapeutics, Inc. advances new therapies for ulcerative colitis and Crohns disease - Traders Union
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95 - Moomoo
LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre Therapeutics (SYRE) price target increased by 42.03% to 88.06 - MSN
SYRE stock jumps more than 70% in a month: What is driving this rally? - MSN
TradingKey - TradingKey
Deutsche Bank Adjusts Spyre Therapeutics Price Target to $102 From $86, Maintains Buy Rating - Moomoo
Deutsche Bank Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $102 - Moomoo
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $107 - Moomoo
UBS Group AG Has $22.30 Million Stake in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics stock hits 52-week high at $76.56 By Investing.com - Investing.com India
Hot Picks: Biotech stocks gain on cancer drugs and trial data - BNN Bloomberg
Spyre Therapeutics stock hits 52-week high at $76.56 - Investing.com
Spyre Therapeutics Insider Sold Shares Worth $5,952,050, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst - The Globe and Mail
F m Investments LLC Acquires 48,825 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $103 - Moomoo
Spyre Therapeutics director Michael Henderson sells $5.95 million in shares - Investing.com India
Insider Sell Alert: Michael Henderson Sells 80,000 Shares of Spy - GuruFocus
Spyre Therapeutics director Michael Henderson sells $5.95 million in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics (SYRE) director sells 80,000 shares in planned trades - Stock Titan
Spyre Therapeutics(SYRE.US) Director Sells US$5.95 Million in Common Stock - Moomoo
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics | SCHEDULE 13G: Others - Moomoo
Citi Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $97 - Moomoo
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $107 - Moomoo
Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Spyre Therapeutics (SYRE) and Adaptive Biotechnologies (ADPT) - The Globe and Mail
Spyre Therapeutics flies on Takeda-rivaling ulcerative colitis results - MSN
Spyre Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $97 to $107 - Moomoo
Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $95 - Moomoo
Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders - TipRanks
Stifel raises Spyre stock price target to $107 on UC data strength - Investing.com
MSN Money - MSN
Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spyre Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Spyre Therapeutics Q1 Loss Widens - Moomoo
Earnings Flash (SYRE) Spyre Therapeutics Posts Q1 Net Loss $0.74 a Share, vs. FactSet Est of $0.67 Loss - marketscreener.com
Spyre Therapeutics, Inc. Q1 operating expenses USD 45.641 million - marketscreener.com
According to the latest financial data from biopharmaceutical company Spyre Therapeutics Inc, as of March 31, 2026, the company's total cash, cash equivalents, and marketable securities amounted to 741.5 millions USD. - bitget.com
Biotech Spyre lines up six 2026 trial readouts with $1.2B cash - Stock Titan
Spyre Therapeutics, Inc. 1Q 2026: Net loss $(69.0)M, EPS $(0.74) — 10-Q Summary - TradingView
Earnings Flash (SYRE) Spyre Therapeutics Posts Q1 Net Loss $0.74 a Share, Vs. FactSet Est of $0.67 Loss - Moomoo
Spyre Therapeutics posts wider-than-expected Q1 net loss - TradingView
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Spyre Therapeutics: Q1 Earnings Snapshot - Barchart.com
SYRE: Strong clinical progress and robust cash position support long-term growth despite higher net loss - TradingView
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):